Physician profile
Barry Gritz
NPI 1487635892
$792,315.13
in general payments reported to CMS, 2019-2025
37 companies · $211K in 2025
The $211K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114K · 2020: $27K · 2021: $64K · 2022: $103K · 2023: $155K · 2024: $119K · 2025: $211K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $423K · Travel and Lodging: $41K · Food and Beverage: $15K · Consulting Fee: $4,870 · Honoraria: $1,150 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $422,916.25 |
| Travel and Lodging | $41,236.13 |
| Food and Beverage | $14,516.68 |
| Consulting Fee | $4,870.00 |
| Honoraria | $1,150.00 |
| Education | $112.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $325,079.28 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $209,468.40 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Supernus Pharmaceuticals, INC. | $87,511.31 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $72,123.37 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $49,306.72 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $20,646.19 | 2019-2025 | Trintellix |
| Corium, LLC | $9,649.48 | 2022-2025 | Azstarys, Azstarys |
| Sunovion Pharmaceuticals INC. | $7,991.46 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,074.21 | 2019-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $1,047.21 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $984.29 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $954.28 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $947.25 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $682.66 | 2019-2025 | Aplenzin, Wellbutrin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $543.23 | 2021-2025 | Caplyta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $506.89 | 2019-2025 | Adzenys Xr-Odt |
| Alkermes, INC. | $499.75 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $497.07 | 2022-2025 | Auvelity, Sunosi |
| Validus Pharmaceuticals LLC | $399.93 | 2019-2025 | Equetro, Equetro |
| Janssen Pharmaceuticals, INC | $345.83 | 2019-2025 | Spravato, Invega Sustenna |
| Tris Pharma INC | $332.94 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Ironshore Pharmaceuticals INC. | $250.82 | 2019-2024 | |
| Almatica Pharma LLC | $195.19 | 2022-2025 | Loreev Xr |
| Harmony Biosciences LLC | $155.66 | 2023-2025 | Wakix |
| Vertical Pharmaceuticals, LLC | $143.40 | 2019-2025 | Relexxii |
| Shire North American Group INC | $135.38 | 2019 | |
| Adlon Therapeutics L.P. | $120.40 | 2019-2020 | |
| Eisai INC. | $112.47 | 2020-2022 | |
| Owp Pharmaceuticals, INC. | $100.52 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $93.35 | 2019-2022 | |
| Noven Therapeutics, LLC | $91.48 | 2022-2024 | Xelstrym |
| Avanir Pharmaceuticals, INC. | $87.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $85.87 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $65.62 | 2024-2025 | Quviviq, Quviviq |
| Rhodes Pharmaceuticals L.P. | $36.32 | 2019 | |
| Currax Pharmaceuticals LLC | $32.94 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $16.15 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Gritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.